Build Your Comparison

Side-by-side financial analysis
PMN logo
PMN
SAVA logo
SAVA
KO logo
KO
Try popular comparisons:

Stock Comparison

PMN vs SAVA vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PMN
ProMIS Neurosciences, Inc.

Biotechnology

HealthcareNASDAQ • CA
Market Cap$68M
5Y Perf.-95.7%
SAVA
Cassava Sciences, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$64M
5Y Perf.+418.2%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+84.9%

PMN vs SAVA vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PMN logoPMN
SAVA logoSAVA
KO logoKO
IndustryBiotechnologyBiotechnologyBeverages - Non-Alcoholic
Market Cap$68M$64M$355.61B
Revenue (TTM)$0.00$0.00$49.28B
Net Income (TTM)$-41M$-106M$13.70B
Gross Margin61.7%
Operating Margin29.3%
Forward P/E25.3x
Total Debt$0.00$0.00$45.49B
Cash & Equiv.$6M$129M$10.27B

PMN vs SAVA vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PMN
SAVA
KO
StockJun 20Jun 26Return
ProMIS Neuroscience… (PMN)1004.3-95.7%
Cassava Sciences, I… (SAVA)100518.2+418.2%
The Coca-Cola Compa… (KO)100184.9+84.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: PMN vs SAVA vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. ProMIS Neurosciences, Inc. is the stronger pick specifically for capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
PMN
ProMIS Neurosciences, Inc.
The Income Pick

PMN is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 1.11
  • Lower volatility, beta 1.11, current ratio 0.88x
  • Beta 1.11 vs SAVA's 1.92
Best for: income & stability and sleep-well-at-night
SAVA
Cassava Sciences, Inc.
The Growth Play

SAVA is the clearest fit if your priority is growth exposure and defensive.

  • EPS growth 77.6%
  • Beta 1.92, current ratio 11.62x
Best for: growth exposure and defensive
KO
The Coca-Cola Company
The Long-Run Compounder

KO carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • 121.1% 10Y total return vs SAVA's -38.0%
  • 1.9% revenue growth vs SAVA's -5.4%
  • 27.8% margin vs SAVA's 5.4%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthKO logoKO1.9% revenue growth vs SAVA's -5.4%
Quality / MarginsKO logoKO27.8% margin vs SAVA's 5.4%
Stability / SafetyPMN logoPMNBeta 1.11 vs SAVA's 1.92
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)KO logoKO+17.2% vs SAVA's -37.7%
Efficiency (ROA)KO logoKO13.1% ROA vs PMN's -151.0%

PMN vs SAVA vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PMNProMIS Neurosciences, Inc.

Segment breakdown not available.

SAVACassava Sciences, Inc.

Segment breakdown not available.

KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

PMN vs SAVA vs KO — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGSAVA

Income & Cash Flow (Last 12 Months)

PMN leads this category, winning 1 of 1 comparable metric.

KO and SAVA operate at a comparable scale, with $49.3B and $0 in trailing revenue.

MetricPMN logoPMNProMIS Neuroscien…SAVA logoSAVACassava Sciences,…KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$0$0$49.3B
EBITDAEarnings before interest/tax-$41M-$110M$15.5B
Net IncomeAfter-tax profit-$41M-$106M$13.7B
Free Cash FlowCash after capex-$35M-$84M$12.6B
Gross MarginGross profit ÷ Revenue+61.7%
Operating MarginEBIT ÷ Revenue+29.3%
Net MarginNet income ÷ Revenue+27.8%
FCF MarginFCF ÷ Revenue+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+12.1%
EPS Growth (YoY)Latest quarter vs prior year+76.0%+62.1%+18.2%
PMN leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

SAVA leads this category, winning 2 of 2 comparable metrics.
MetricPMN logoPMNProMIS Neuroscien…SAVA logoSAVACassava Sciences,…KO logoKOThe Coca-Cola Com…
Market CapShares × price$68M$64M$355.6B
Enterprise ValueMkt cap + debt − cash$61M-$65M$390.8B
Trailing P/EPrice ÷ TTM EPS-0.46x-2.54x27.18x
Forward P/EPrice ÷ next-FY EPS est.25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple26.39x
Price / SalesMarket cap ÷ Revenue7.42x
Price / BookPrice ÷ Book value/share0.42x10.40x
Price / FCFMarket cap ÷ FCF67.15x
SAVA leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 5 of 7 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-2 for PMN. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs PMN's 0/9, reflecting strong financial health.

MetricPMN logoPMNProMIS Neuroscien…SAVA logoSAVACassava Sciences,…KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-2.4%-95.8%+41.1%
ROA (TTM)Return on assets-151.0%-75.3%+13.1%
ROICReturn on invested capital-6.3%+15.8%
ROCEReturn on capital employed-5.2%-99.9%+17.3%
Piotroski ScoreFundamental quality 0–9027
Debt / EquityFinancial leverage1.33x
Net DebtTotal debt minus cash-$6M-$129M$35.2B
Cash & Equiv.Liquid assets$6M$129M$10.3B
Total DebtShort + long-term debt$0$0$45.5B
Interest CoverageEBIT ÷ Interest expense10.70x
KO leads this category, winning 5 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

KO leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $363 for PMN. Over the past 12 months, KO leads with a +17.2% total return vs SAVA's -37.7%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs PMN's -56.0% — a key indicator of consistent wealth creation.

MetricPMN logoPMNProMIS Neuroscien…SAVA logoSAVACassava Sciences,…KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date+45.0%-36.8%+20.3%
1-Year ReturnPast 12 months-20.4%-37.7%+17.2%
3-Year ReturnCumulative with dividends-91.5%-62.5%+47.0%
5-Year ReturnCumulative with dividends-96.4%-87.8%+65.6%
10-Year ReturnCumulative with dividends-91.4%-38.0%+121.1%
CAGR (3Y)Annualised 3-year return-56.0%-27.9%+13.7%
KO leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than SAVA's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs PMN's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPMN logoPMNProMIS Neuroscien…SAVA logoSAVACassava Sciences,…KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5001.11x1.92x-0.20x
52-Week HighHighest price in past year$39.75$4.98$84.04
52-Week LowLowest price in past year$6.27$1.27$65.35
% of 52W HighCurrent price vs 52-week peak+26.0%+26.5%+98.3%
RSI (14)Momentum oscillator 0–10051.842.760.6
Avg Volume (50D)Average daily shares traded34K134K12.7M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 1 of 1 comparable metric.

Analyst consensus: PMN as "Buy", SAVA as "Buy", KO as "Buy". Consensus price targets imply 73.9% upside for PMN (target: $18) vs 4.2% for KO (target: $86). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricPMN logoPMNProMIS Neuroscien…SAVA logoSAVACassava Sciences,…KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$18.00$86.13
# AnalystsCovering analysts21248
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises056
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.2%
KO leads this category, winning 1 of 1 comparable metric.
Key Takeaway

KO leads in 4 of 6 categories (Profitability & Efficiency, Total Returns). PMN leads in 1 (Income & Cash Flow).

Best OverallThe Coca-Cola Company (KO)Leads 4 of 6 categories
Loading custom metrics...

PMN vs SAVA vs KO: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is PMN or SAVA or KO a better buy right now?

The Coca-Cola Company (KO) offers the better valuation at 27.

2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate ProMIS Neurosciences, Inc. (PMN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — PMN or SAVA or KO?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -96. 4% for ProMIS Neurosciences, Inc. (PMN). Over 10 years, the gap is even starker: KO returned +121. 1% versus PMN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — PMN or SAVA or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately -1060% more volatile than KO relative to the S&P 500.

04

Which is growing faster — PMN or SAVA or KO?

On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.

grew EPS 77. 6% year-over-year, compared to -922. 2% for ProMIS Neurosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — PMN or SAVA or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus 0. 0% for Cassava Sciences, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 0. 0% for SAVA. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is PMN or SAVA or KO more undervalued right now?

Analyst consensus price targets imply the most upside for PMN: 73.

9% to $18. 00.

07

Which pays a better dividend — PMN or SAVA or KO?

In this comparison, KO (2.

5% yield) pays a dividend. PMN, SAVA do not pay a meaningful dividend and should not be held primarily for income.

08

Is PMN or SAVA or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, SAVA: -38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between PMN and SAVA and KO?

These companies operate in different sectors (PMN (Healthcare) and SAVA (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

KO pays a dividend while PMN, SAVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.